Share on StockTwits

Cambrex Corp. (NYSE:CBM) released its earnings data on Tuesday. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.21 by $0.11, Analyst Ratings reports.

Cambrex Corp. (NYSE:CBM) opened at 21.47 on Tuesday. Cambrex Corp. has a 1-year low of $12.56 and a 1-year high of $23.88. The stock’s 50-day moving average is $21.46 and its 200-day moving average is $20.39. The company has a market cap of $658.7 million and a P/E ratio of 20.42.

A number of research firms have recently commented on CBM. Analysts at Zacks upgraded shares of Cambrex Corp. from a “neutral” rating to an “outperform” rating in a research note on Monday. They now have a $23.20 price target on the stock. On the ratings front, analysts at First Analysis downgraded shares of Cambrex Corp. from an “overweight” rating to an “equal weight” rating in a research note on Friday. Finally, analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

In other Cambrex Corp. news, SVP William M. Haskel sold 28,100 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $22.50, for a total transaction of $632,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.